Peptide Synthesis Market Worth 426.4 Million USD by 2023
PUNE, India, July 16, 2018 /PRNewswire/ --
According to a new market research report "Peptide Synthesis Market by Product (Reagent, Synthesizer, Chromatography), Technology (Solid Phase, Liquid Phase, and Hybrid & Recombinant), End User (Pharmaceuticals & Biotechnology, CRO), and Region - Global Forecast to 2023", published by MarketsandMarkets™, the market is projected to reach USD 426.4 million by 2023 from USD 310.5 million in 2018, at a CAGR of 6.5% during the forecast period.
(Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )
Browse 92 market data Tables and 29 Figures spread through 135 Pages and in-depth TOC on "Peptide Synthesis Market"
https://www.marketsandmarkets.com/Market-Reports/peptide-synthesis-market-158927365.html
Early buyers will receive 10% customization on this report
Growth in this market is driven by the increasing use of peptides in pharmaceutical drugs, rise in research activities and availability of funding for R&D, and the development of advanced technological peptide synthesizers.
Reagents accounted for the largest share of the Peptide Synthesis Market in 2017
By product, the market is segmented into reagents & equipment. In 2017, reagents segment accounted for the largest share of the Peptide Synthesis Market. The large share of this segment can be attributed to factors such as the growing applications of peptides in therapeutics, drug design, and gene synthesis; rising number of ongoing research projects involving peptide synthesis; and the availability of various peptide synthesis reagents in the market.
By technology, solid-phase synthesis is expected to grow at the highest CAGR during 2018-2023
Based on technology, the Peptide Synthesis Market has been segmented into solid-phase synthesis, liquid-phase synthesis and recombinant technology. In 2017, solid-phase synthesis is expected to grow at the highest CAGR during 2018-2023. Solid-phase synthesis is associated with a number of advantages, such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids. Such advantages are driving the growth of the solid-phase synthesis segment.
Pharmaceutical & biotechnological companies are expected to dominate the Peptide Synthesis Market in 2017
Based on end users, the Peptide Synthesis Market is segmented into pharmaceutical & biotechnological companies, contract development and manufacturing organizations, and academic and research institutes. In 2017, pharmaceutical & biotechnological companies accounted for the largest market share due to increasing number of research projects in genomics, molecular biology, and related areas; growing application areas of peptides in drug discovery, therapeutics, and research; and substantial R&D investments.
Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=158927365
APAC is expected to grow at the highest CAGR during the forecast period.
Global Peptide Synthesis Market has been studied for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. APAC is expected to grow at the highest CAGR in the Peptide Synthesis Market, primarily due to the increasing investments by pharmaceutical and biotechnology companies and rising R&D activities in the region.
The prominent players in the Peptide Synthesis Market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGaA (Germany) and New England Peptide, Inc (US). Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the Peptide Synthesis Market.
Know more about the Peptide Synthesis Market:
https://www.marketsandmarkets.com/Market-Reports/peptide-synthesis-market-158927365.html
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: [email protected]
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/peptide-synthesis-market.asp
Connect with us on LinkedIn: http://www.linkedin.com/company/marketsandmarkets
Share this article